MNG381
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.476
- ALLOGRAFT_REJECTION+0.366
- HYPOXIA+0.361
- OXIDATIVE_PHOSPHORYLATION+0.357
- GLYCOLYSIS+0.326
- TNFA_SIGNALING_VIA_NFKB+0.322
- INFLAMMATORY_RESPONSE+0.299
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.292
- ADIPOGENESIS+0.284
- COAGULATION+0.284
Top 10 suppressed
- TGF_BETA_SIGNALING-0.136
- APICAL_JUNCTION-0.129
- ANDROGEN_RESPONSE-0.121
- ESTROGEN_RESPONSE_EARLY-0.082
- G2M_CHECKPOINT-0.077
- MITOTIC_SPINDLE-0.073
- DNA_REPAIR-0.056
- CHOLESTEROL_HOMEOSTASIS-0.050
- SPERMATOGENESIS-0.040
- ESTROGEN_RESPONSE_LATE-0.037
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG919 | — | — | 0.803 |
| 2 | MNG1189 | — | — | 0.797 |
| 3 | BS_JG9JZTA9 | low-grade glioma | — | 0.792 |
| 4 | AUR-AF98-TTM1-A-1-1-R-A742-41 | — | E | 0.791 |
| 5 | X3a5c813b.6c47.49aa.916c.bcddbafdd54b | — | cohortA1 | 0.789 |
| 6 | AUR-AER6-TTM3-A-1-1-R-A742-41 | — | C | 0.780 |
| 7 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.778 |
| 8 | SRR8518316 | — | D | 0.775 |
| 9 | TCGA-ZF-AA53-01A-11R-A39I-07 | — | — | 0.773 |
| 10 | SRR12696756 | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.476 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.366 | Idelalisib | — uncovered |
| HYPOXIA | 0.361 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.357 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.326 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.322 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.299 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.292 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.284 | Inavolisib | — uncovered |
| COAGULATION | 0.284 | Binimetinib | — uncovered |
| COMPLEMENT | 0.266 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.261 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.261 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.256 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.221 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.219 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.198 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.195 | Idelalisib | — uncovered |